Ahmad Walid Ayas1, Stefan Grau2, Karolina Jablonska1, Daniel Ruess3, Maximilian Ruge3, Simone Marnitz1, Roland Goldbrunner2, Martin Kocher4,5,6. 1. Department of Radiation Oncology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany. 2. Department of Neurosurgery, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany. 3. Department of Stereotactic and Functional Neurosurgery, Center for Integrated Oncology, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany. 4. Department of Radiation Oncology, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany. martin.kocher@uk-koeln.de. 5. Department of Stereotactic and Functional Neurosurgery, Center for Integrated Oncology, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany. martin.kocher@uk-koeln.de. 6. Institute of Neuroscience and Medicine (INM-4), Forschungszentrum Juelich, Juelich, Germany. martin.kocher@uk-koeln.de.
Abstract
PURPOSE: Evaluation of postoperative fractionated local 3D-conformal radiotherapy (3DRT) of the resection cavity in brain metastases. PATIENTS AND METHODS: Between 2011 and 2016, 57 patients underwent resection of a single, previously untreated (37/57, 65%) or recurrent (20/57, 35%) brain metastasis (median maximal diameter 3.5 cm [1.1-6.5 cm]) followed by 3DRT. For definition of the gross tumor volume (GTV), the resection cavity was used and for the clinical target volume (CTV), margins of 1.0-1.5 cm were added. Median dose was 48.0 Gy (30.0-50.4 Gy) in 25 (10-28) fractions; most patients had 36.0-42.0 Gy in 3.0 Gy fractions (n = 16, EQD210Gy 39.0-45.5 Gy) or 40.0-50.4 Gy in 1.8-2.0 Gy fractions (n = 37, EQD210Gy 39.3-50.0 Gy). RESULTS: Median follow-up was 18 months. Local control rates were 83% at 1 year and 78% at 2 years and were significantly influenced by histology (breast cancer 100%, non-small lung cancer 87%, melanoma 80%, colorectal cancer 26% at 2 years, p = 0.006) and resection status (p < 0.0001), but not by EQD210Gy or size of the planning target volume (median 96.7 ml [16.7-282.8 ml]). At 1 and 2 years, 74% and 52% of the patients were free from distant brain metastases. Salvage procedures were applied in 25/27 (93%) of recurrent patients. Survival was 68% at 1 year and 41% at 2 years and was significantly improved in younger patients (p = 0.006) with higher Karnofsky performance score (p < 0.0001) and without prior radiotherapy (54% vs. 9% at 2 years, p = 0.006). No cases of radiographic or symptomatic radionecrosis were observed. CONCLUSION: Adjuvant fractionated local 3DRT is highly effective in radiosensitive, completely resected metastases and should be considered for treating large resection cavities as an alternative to postoperative stereotactic single dose or hypofractionated radiosurgery.
PURPOSE: Evaluation of postoperative fractionated local 3D-conformal radiotherapy (3DRT) of the resection cavity in brain metastases. PATIENTS AND METHODS: Between 2011 and 2016, 57 patients underwent resection of a single, previously untreated (37/57, 65%) or recurrent (20/57, 35%) brain metastasis (median maximal diameter 3.5 cm [1.1-6.5 cm]) followed by 3DRT. For definition of the gross tumor volume (GTV), the resection cavity was used and for the clinical target volume (CTV), margins of 1.0-1.5 cm were added. Median dose was 48.0 Gy (30.0-50.4 Gy) in 25 (10-28) fractions; most patients had 36.0-42.0 Gy in 3.0 Gy fractions (n = 16, EQD210Gy 39.0-45.5 Gy) or 40.0-50.4 Gy in 1.8-2.0 Gy fractions (n = 37, EQD210Gy 39.3-50.0 Gy). RESULTS: Median follow-up was 18 months. Local control rates were 83% at 1 year and 78% at 2 years and were significantly influenced by histology (breast cancer 100%, non-small lung cancer 87%, melanoma 80%, colorectal cancer 26% at 2 years, p = 0.006) and resection status (p < 0.0001), but not by EQD210Gy or size of the planning target volume (median 96.7 ml [16.7-282.8 ml]). At 1 and 2 years, 74% and 52% of the patients were free from distant brain metastases. Salvage procedures were applied in 25/27 (93%) of recurrent patients. Survival was 68% at 1 year and 41% at 2 years and was significantly improved in younger patients (p = 0.006) with higher Karnofsky performance score (p < 0.0001) and without prior radiotherapy (54% vs. 9% at 2 years, p = 0.006). No cases of radiographic or symptomatic radionecrosis were observed. CONCLUSION: Adjuvant fractionated local 3DRT is highly effective in radiosensitive, completely resected metastases and should be considered for treating large resection cavities as an alternative to postoperative stereotactic single dose or hypofractionated radiosurgery.
Authors: Bree R Eaton; Michael J LaRiviere; Michael J La Riviere; Sungjin Kim; Roshan S Prabhu; Kirtesh Patel; Shravan Kandula; Nelson Oyesiku; Jeffrey Olson; Walter Curran; Hui-Kuo Shu; Ian Crocker Journal: J Neurooncol Date: 2015-04-11 Impact factor: 4.130
Authors: Cameron Brennan; T Jonathan Yang; Patrick Hilden; Zhigang Zhang; Kelvin Chan; Yoshiya Yamada; Timothy A Chan; Stella C Lymberis; Ashwatha Narayana; Viviane Tabar; Philip H Gutin; Åse Ballangrud; Eric Lis; Kathryn Beal Journal: Int J Radiat Oncol Biol Phys Date: 2014-01-01 Impact factor: 7.038
Authors: Eric Ojerholm; John Y K Lee; Jayesh P Thawani; Denise Miller; Donald M O'Rourke; Jay F Dorsey; Geoffrey A Geiger; Suneel Nagda; James D Kolker; Robert A Lustig; Michelle Alonso-Basanta Journal: J Neurosurg Date: 2014-12 Impact factor: 5.115
Authors: Brian J Blonigen; Ryan D Steinmetz; Linda Levin; Michael A Lamba; Ronald E Warnick; John C Breneman Journal: Int J Radiat Oncol Biol Phys Date: 2009-09-23 Impact factor: 7.038
Authors: Sidyarth Garimall; Mihir Shanker; Erin Johns; Trevor Watkins; Sarah Olson; Michael Huo; Matthew C Foote; Mark B Pinkham Journal: J Neurooncol Date: 2020-01-06 Impact factor: 4.130
Authors: Pantelis Stavrinou; Lars Plambeck; Martin Proescholdt; Markus Ghadimi; Roland Goldbrunner; Stefan Grau Journal: Medicine (Baltimore) Date: 2019-08 Impact factor: 1.889
Authors: Rami A El Shafie; Thorsten Dresel; Dorothea Weber; Daniela Schmitt; Kristin Lang; Laila König; Simon Höne; Tobias Forster; Bastian von Nettelbladt; Tanja Eichkorn; Sebastian Adeberg; Jürgen Debus; Stefan Rieken; Denise Bernhardt Journal: Front Oncol Date: 2020-05-08 Impact factor: 6.244
Authors: Sergej Telentschak; Daniel Ruess; Stefan Grau; Roland Goldbrunner; Niklas von Spreckelsen; Karolina Jablonska; Harald Treuer; Martin Kocher; Maximilian Ruge Journal: J Cancer Res Clin Oncol Date: 2021-02-26 Impact factor: 4.553
Authors: Stephanie T Jünger; Lenhard Pennig; Petra Schödel; Roland Goldbrunner; Lea Friker; Martin Kocher; Martin Proescholdt; Stefan Grau Journal: Cancers (Basel) Date: 2021-03-21 Impact factor: 6.639